MRK Stock Recent News

The market has largely priced in the 2028 Keytruda patent cliff, with Merck trading at a discount reflecting aggressive revenue erosion assumptions. Merck is actively expanding in oncology, immunology, and vaccines through acquisitions and R&D, offering long-term optionality beyond Keytruda. Gardasil's China-driven slump has limited downside left, with stable ex-China growth and male-use approval offering medium-term recovery potential.

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4 in Chicago. The presentations include the Phase 3 MANEUVER data for potentially best-in-class pimicotinib in the treatment of the rare tumor TGCT, as well as data from both company- and investigator-sponsored studies highlighting the com.

Merck & Co. is undervalued, trading at lower multiples than peers, due to concerns over patent expirations and recent financial volatility. Despite modest overall revenue growth, oncology—especially Keytruda—drives strong segment performance, offsetting declines in virology and diabetes products. Management is aggressively investing in R&D and manufacturing expansion, with a robust drug pipeline and significant capital commitments to future growth.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference.

DARMSTADT, Germany--(BUSINESS WIRE)--Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced positive data on enpatoran, an investigational, oral, novel TLR7/8 inhibitor, demonstrating clinically meaningful reduction in disease activity in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) with active lupus rash. The findings are from Cohort A of the Phase 2 WILLOW study (NCT05162586). Results will be.

The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.

I'm targeting value in overlooked sectors, highlighting Merck and Federal Realty as top picks for income and upside potential. Merck offers a low 8.5x PE, a 4.3% yield, a robust drug pipeline, and resilient growth despite Gardasil headwinds and tariff pressures. Federal Realty has premier assets, rising occupancy, low tenant risk, and a 4.5% yield, trading well below historical valuation multiples.

There are over 12,000 publicly traded stocks in the United States; not even the most intelligent investors with the best tools can immediately find them. Many investors and traders typically maintain a small list of key stocks they follow when seeking capital gains or high-yield dividends. At 24/7 Wall St., we keep a list of stocks that we consider to be the kind of companies that can outperform regardless of the current market conditions. These companies have iconic brand names, offer products or services that never go out of style, and pay big dividends. 24/7 Wall St. Key Points: Financial media continues to look for a market bottom, which may have been put in. Despite pressure from the U.S. president, it is unlikely the Federal Reserve will lower rates this summer. Passive income from quality dividend stocks always makes sense. Are you generating passive income in your portfolio? Why not meet with a financial advisor near you for a complete asset review? Click here to get started fi

Both PFE and MRK have strong product and pipeline portfolios in oncology.